About ISB

In Silico Biosciences, Inc. (ISB) was founded in 2000 on the premise of modeling complex CNS disorders using advanced mathematical techniques. ISB is the only company in the world to combine the academic discipline of computational neurosciences with pharmacological and disease-related concepts with a laser-sharp focus on practical questions in pharmaceutical research and development. ISB has worked with 12 pharmaceutical companies (nine of them in the top-20) and three patient foundations. The platform of ISB prospectively, blindly, and correctly predicted three clinical trial outcomes with completely new targets in Alzheimer’s disease and schizophrenia. The company has published over 20 peer-reviewed papers and was able to secure international patents on the software platform, a first in biomedical modeling and simulation.

The company employs Quantitative Systems Pharmacology (QSP), involving a complex computer model of firing activity in biologically based neuronal circuits, employing formalized domain expertise in neuroscience. Since 2000, In Silico Biosciences, Inc. has used QSP to support central nervous system research and development, making modeled results actionable with practical applications.

In 2020, ISB joined nine European institutions to help patients suffering from chronic pain. The result: QSPainRelief, a five-year, six-million-dollar pharmacological pain relief project. Led by world renowned experts on chronic pain, pharmacology, pharmacogenomics, personalized medicine, systems biology, and computer modeling, the QSPainRelief consortium is developing a validated computational model for identifying optimal personalized combination treatments of existing medications for individual patients.